west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "表皮生长因子" 80 results
  • Combined Inhibition of Epidermal Growth Factor and Cyclooxygenase-2 Signaling Pathways in Non-small Cell Lung Cancer Therapy

    The resistance of non-small cell lung cancer (NSCLC) to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has been brought into focus. COX-2 signal pathway was found to be closely related to EGFR signal pathway by recent researches, and there has been a growing interest to focus the researches on whether COX-2 pathway inhibition improves the efficacy of EGFR-TKIs in treating advanced NSCLC. In this review, we will illustrate recent advances of combined inhibition of EGFR and COX-2 signal pathways in NSCLC therapy.

    Release date: Export PDF Favorites Scan
  • Expressions and Significance of Epidermal Growth Factor Receptor, HER-2 and Cyclooxygenase-2 in Gastric Carcinoma

    目的 探讨胃癌组织中人表皮生长因子受体(EGFR)、表皮生长因子受体-2(HER-2)和环氧合酶-2(COX-2)的表达及与临床病理特征的关系。 方法 应用免疫组织化学Envision二步法,检测70例胃癌组织中EGFR、HER-2和COX-2的表达情况,并结合其临床病理特点进行分析。 结果 EGFR、HER-2和COX-2在胃癌组织中的表达阳性率分别为35.7%(25/70)、27.1%(19/70)、67.1%(47/70)。阳性表达与肿瘤分化程度、侵袭深度、有无淋巴结转移及TNM分期有关(P<0.05),而与患者的性别及年龄、肿瘤部位和大小无关(Pgt;0.05)。EGFR、HER-2和COX-2三者之间在胃癌组织中的表达均呈正相关(P<0.05)。 结论 EGFR、HER-2和COX-2的表达参与胃癌的生长、侵袭和转移过程。它们的联合检测有助于胃癌患者靶向药物的选择,也为胃癌的预后判断提供客观的参考指标。Objective To observe the expressions of epidermal growth factor receptor (EGFR), HER-2 and cyclooxygenase-2 (COX-2) in gastric carcinoma (GC) and to explore the relationship among them. Methods The envision immunohistochemical stain method was used to detect EGFR, HER-2 and COX-2 protein expressions in sample of 70 GC tissues. And their corresponding pathologic features were analyzed. Results  The positive expression rates of EGFR, HER-2 and COX-2 protein in GC tissue were 35.7% (25/70), 27.1% (19/70) and 67.1% (47/70), respectively. The positive expression rates were closely relevant to the differentiation of the cancer, invasion depth, lymphatic metastasis and TNM (P<0.05), but not to the patient’ s sex, age, tumor site and size (P>0. 05). There was a stable positive correlation among EGFR, HER-2 and COX-2 expressions in GC tissues, respectively. Conclusions EGFR, HER-2 and COX-2 expressions participate in the development, invasion and metastasis process of GC. Combined detection can be regarded as an important symbol for guiding the molecular targeting therapy of GC, and judging the prognosis of GC.

    Release date: Export PDF Favorites Scan
  • Expressions and Clinical Significance of P-gp, GST-π and C-erbB-2 in Breast Cancer

    Objective To investigate the relationship between the expressions of P-gp, GST-π and C-erbB-2 and clinicopathologic characteristics as well as prognosis in breast cancer. Methods The expressions of P-gp, GST-π and C-erbB-2 were detected by immunohistochemistry in 48 cases of breast cancer, and histopathologic characteristics as well as 5-year survival rate of these cases were analyzed. Results There was no significant difference in the expressions of P-gp and GST-π with age, histologic grade, number of lymph node metastasis and TNM stage of breast cancer ( P > 0.05). There was significant difference in expression of C-erbB-2 with histologic grade, number of lymph node metastasis and TNM stage of breast cancer ( P < 0.05). Positive rate of P-gp expression in breast cancer with positive C-erbB-2 expression was remarkably higher than that in breast cancer with negative C-erbB-2 expression ( P < 0.05) . Positive rate of GST-π and C-erbB-2 expression in survivals within 5 years was remarkably lower than that in deaths within 5 years ( P < 0.01). Conclusion P-gp participates primary drug-resistance mechanism of breast cancer. The possibility of primary drug-resistance is higher in breast cancer with positive C-erbB-2 expression. The expression of C-erbB-2 helps to evaluate prognosis and the result of treatment in breast cancer.

    Release date:2016-08-28 03:48 Export PDF Favorites Scan
  • Effect of Recombinant Epidermal Growth Factor on Small Bowel Anastomotic Wound Healing

    【Abstract】ObjectiveTo study the positive effect of recombinant human epidermal growth factor (rhEGF) on rabbit intestinal anastomotic wound healing after bowel resection. MethodsFortyeight white rabbits were randomly divided into study group in which rhEGF was injected and spinged in the submucosa and mucosa respectively during intestinal anastomosis after bowel resection, and control group in which only intestinal resection and anastomosis was performed. The leukocyte was counted. The incidence of anastomotic leakage and the synthesis of collagen fibrils and hydroxyproline were observed. ResultsThe leukocyte numbers in the anastomotic tissue in two groups rabbits increased slightly 3 d, 5 d and 7d after intestinal anastomosis, but the difference between study group and control group was insignificant (Pgt;0.05). The incidence of anastomotic leakage in the control group (16.7%) was higher than that of the study group (4.3%). The area of collagen fibrils 3 d, 5 d and 7d after intestinal anastomosis in the study group were significantly more than that in the control group (P<0.05). Number of fibroblast was higher in the study group and the cells appeared bigger nucleus and dense colouration as well as enriched plasm. Angiogenesis in anastomosis tissue in the study group was significant and normal structure was present. Cell structure of anastomosis mucosa was damaged in the control group. Synthesis of hydroxyproline in anastomotic tissue 5 d and 7 d after anastomosis in the study group was more than that in the control group (P<0.05).ConclusionInflammation was present in the whole process of wound healing, and local using of EGF had insignificant effect on system inflammation. EGF functions as chemoattractant and increases the recruitment of leukocytes, monocytes and fibroblasts into the wound area. EGF increases the production of collagen, angiogenesis and the synthesis of hydroxyproline. So EGF could promote wound healing and protect from anastomosis leakage in this study.

    Release date:2016-08-28 04:30 Export PDF Favorites Scan
  • EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR IN HUMAN THYROID CARCINOMAS

    To investigate the significance of epidermal growth factor receptor (EGFR) in thyroid carcinoma, the expression of EGFR in 81 samples of thyroid carcinoma were determined by immunohistochemical SP method and comparison among thyroid carcinoma, thyroid adenomas and normal thyroid tissue adjacent to the cancer were made. The results showed: EGFR expression was positive in 45 cases (55.6%) of thyroid carcinoma with no positive expression either in thyroid adenomas or normal thyroid tissue adjacent to the cancer (P<0.01). There were no statistical differences between EGFR positive rate and thyroid carcinomatous pathological type, clinical stage, depth of invasion, lymph node metastasis or patients′ postoperative survival time (P>0.05). This data suggests that expression of EGFR in thyroid carcinoma is associated with its autonomous growth and malignant phenotype, but it is probably not a useful index for assessing the biological behavious and prognosis of thyroid carcinoma.

    Release date:2016-08-29 09:20 Export PDF Favorites Scan
  • Detection of EGFR Exon 19 and 21 Mutations in Pleural Effusion from Non-Small-Cell Lung Cancer Patients by Mutant Enriched PCR Assay

    Objective To investigate the feasibility of detection of epidermal growth factor receptor ( EGFR) exon 19 deletions and exon 21 L858R mutations in pleural effusion fromnon-small-cell lung cancer ( NSCLC) patients by mutant enriched PCR assay. Methods The mutations of exon 19 and 21 of EGFR gene in pleural samples fromthirty NSCLC patients were analyzed using both the mutant-enriched PCR assay and the non-enriched PCR assay. Results Ten ( 33. 3% , 10/ 30) exon 19 deletions and five ( 16. 7% , 5/30) exon 21 L858R mutation were detected by the mutant-enriched PCR assay, while only 6 cases ( 20. 0% ) and 1 case ( 3. 3% ) were detected by the non-enriched PCR assay respectively. The difference of mutation detection rate of EGFR gene between the two methods was statistically significant ( P = 0. 032) . Mutations were detected in all of partial responders ( 2 /4) among the four patients who received gefitinib therapy. Conclusions Mutant-enriched PCR assay can detect EGFR exon 19 deletions and exon 21 L858R mutation in pleural effusion from NSCLC patients effectively, economically and accurately. It may be a valuable biomarker for gefitinib therapy in advanced NSCLC.

    Release date:2016-09-14 11:24 Export PDF Favorites Scan
  • Effects of Chronic Aspergillus Fumigatus Exposure on Epithelial Cell Injury and Expression of Epidermal Growth Factor Receptor in Airways of Asthmatic Rats

    Objective To explore the effects of prolonged inhalation of Aspergillus fumigatus ( Af)spores on epithelial cell injury and expression of epidermal growth factor receptor( EGFR) in airways of asthmatic rats. Methods 64 male Wistar rats were randomly divided into 8 groups, ie. chronic asthma group ( group A) , chronic asthma plus Af spores inhalation for 1 week ( group B) , 3 weeks ( group C) and 5 weeks ( group D) , chronic asthma plus saline inhalation for 5 weeks ( group E) , OVA-sensitized and salinechallenged group ( group F) , and OVA-sensitized and saline-challenged plus Af spores inhalation for 5 weeks ( group G) ( each n =8) . The airway resistance ( Raw) and change of Raw after acetylcholine provocation were detected using a computerized system. The concentrations of epidermal growth factor ( EGF) andtransforming growth factor alpha( TGF-α) in BALF were measured by ELISA. The extents of epithelial cell injury and goblet cell hyperplasia were evaluated on hematoxylin and eosin-stained( HE) and periodic acidschiff ( PAS) stained lung sections. The expression of EGFR in airway epithelia was demonstrated byimmunohistochemistry, and the level of EGFR protein in the rat lung tissues was measured by western blot.Results The concentration of EGF( pg/mL) ( 51. 72 ±8. 54, 68. 12 ±7. 85, 86. 24 ±9. 12, respectively)and TGF-α( pg/mL) ( 55. 26 ±9. 30, 75. 58 ±11. 56, 96. 75 ±14. 66, respectively) , detached/ inner perimeter of epithelium( % ) ( 11. 25 ±3. 12, 26. 45 ±5. 56, 28. 50 ±7. 50, respectively) , the ratio of goblet cell area to epithelial cell area ( % ) ( 16. 42 ±5. 24, 22. 64 ±6. 82, 36. 38 ±9. 21, respectively) , the integrated optical density ( IOD) of EGFR positive stain in airway epithelial cells ( 82 ±15,120 ±19, 165 ±21, respectively) , and the EGFR protein levels in lung tissues ( 0. 91 ±0. 26, 1. 61 ±0. 52, 2. 52 ±0. 78,respectively) in group B, C, and D were higher than those in group A, E, F and G( P lt; 0. 05 or P lt;0. 01) .The change rates of Raw( % ) ( 61. 91 ±5. 26, 84. 69 ±6. 38) in group C and D were higher than those in group A, E, F and G ( P lt; 0. 05 or P lt;0. 01) . The IOD of EGFR was positively correlated with detached/inner perimeter of epithelium( % ) and the ratio of goblet cell area to epithelial cell area( % ) ( r = 0. 692,P lt;0. 01; r = 0. 657, P lt; 0. 01, respectively) . Conclusion Prolonged inhalation of Aspergillus fumigatus spores can aggravate airway epithelial cell injury, up-regulate the expression of EGFR in airway epithelial cell and induce goblet cell hyperplasia, thus increase the airway responsiveness in rats with chronic asthma.

    Release date:2016-08-30 11:53 Export PDF Favorites Scan
  • Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Prevent Bleomycin-Induced Lung Fibrosis in Mice

    Objective To evaluate the effects of two different epidermal growth factor receptor tyrosine kinase inhibitors ( EGFR-TKIs) , Gefitinib and Erlotinib, on lung fibrosis induced by bleomycin.Methods Forty BALB/c female mice were randomly divided into four groups, ie. a control group( saline given orally and intratracheally) , a fibrosis group( saline given orally with bleomycin instillation) , a Gefitnib group( Gefitnib 20 mg/kg given orally with bleomycin instillation) , and an Erlotinib group ( Erlotinib25 mg/kg given orally with bleomycin instillation) . Bleomycin ( 3 mg/kg) was intratracheally instilled on the first day. Gefitinib or Erlotinib was given orally daily and normal saline as control. Then they were sacrificed by abdominal aortic bleeding 14 days after the bleomycin instillation. The left lung was stained with HE and Masson’s trichrome staining respectively for pathological examination. Total EGFR and phosphorylated EGFR were detected by immunohistochemistry. Hydroxyproline ( HYP) assay was performed in the right lung.Results Both Gefitinib and Erlotinib significantly reduced lung collagen accumulation and the content of HYP. Immunohistochemistry revealed that phosphorylation of EGFR in lung mesenchymal cells induced by bleomycin was inhibited. Furthermore, there was no difference between Gefitinib and Erlotinib in inhibiting lung fibrosis. Conclusion Our findings suggest that, in the preclinical setting, EGFR-TKIs may have aprotective effect on lung fibrosis induced by bleomycin.

    Release date:2016-08-30 11:53 Export PDF Favorites Scan
  • 吉非替尼或化疗治疗突变表皮生长因子受体非小细胞肺癌( Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.)

    吉非替尼或化疗治疗突变表皮生长因子受体非小细胞肺癌(Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR) 【摘要翻译】 背景: 吉非替尼一类的表皮生长因子受体( EGFR) 酪氨酸酶抑制剂对EGFR 敏感性突变的非小细胞肺癌治疗效果较好, 但目前对这种疗法与标准化疗在有效性和安全性方面的差异了解较少。方法: 我们共纳入230 例EGFR 突变的非小细胞肺癌患者, 这些患者均有转移但此前未接受卡铂-泰素化疗或吉非替尼治疗。主要终点是无进展的生存时间, 次要终点包括整体生存时间、治疗有效率和不良反应。结果: 按计划对最初的200 例患者进行interim分析发现吉非替尼治疗组无进展的生存时间显著高于标准化疗组( 吉非替尼组死亡或疾病进展的风险比为0. 36, P lt;0. 001) ,因此提前结束本研究。吉非替尼组中位数无进展的生存时间较长( 吉非替尼组10. 8 个月, 化疗组5. 4 个月, 风险比0. 30;95% CI 0. 22 ~0. 41; P lt; 0. 001) , 有效率也较高( 分别为73. 7% 和30. 7% , P lt;0. 001) 。中位数整体生存时间吉非替尼组为30. 5 个月, 化疗组为23. 6 个月( P =0. 31) 。吉非替尼最常见的不良反应为皮疹( 71. 1% ) 和转氨酶增高( 55. 3% ) ,化疗组最常见的不良反应是中性粒细胞减少( 77. 0% ) 、贫血( 55. 3%) 、纳差( 56. 6% ) 及感觉神经病变( 54. 9% ) 。1 例服用吉非替尼的患者死于肺间质纤维化。结论: 与标准化疗相比, 吉非替尼可改善无进展的生存时间, 不良反应较小, 可作为EGFR 突变的晚期非小细胞肺癌一线治疗。 【述评】 目前对晚期非小细胞肺癌仍缺乏有效治疗方法。临床通常采用含铂化疗方案, 在无效的情况下选择EGFR 酪氨酸酶抑制剂。本研究通过PNA-LNA PCR 检测EGFR 突变, 敏感性达到97% , 特异性为100% 。通过这种方法筛选出EGFR 突变非小细胞肺癌患者进行吉非替尼治疗,效果明显好于标准化疗组, 这种检测方法和治疗方案值得临床推广。尽管如此, EGFR 突变毕竟只占非小细胞肺癌中的一小部分, 并且, 在服用EGFR 酪氨酸激酶抑制剂后出现耐药后疾病快速进展在临床上较为棘手。因此, 进一步研究肺癌发病机制, 探索新的治疗靶点对肺癌治疗仍具有紧迫性。

    Release date:2016-08-30 11:54 Export PDF Favorites Scan
  • Clinical Significance of Epidermal Growth Factor Receptor Mutations from Patients with Non-Small Cell Lung Cancer

    Objective To evaluate the clinical significance of epidermal growth factor receptor EGFR) mutations in the treatment of non-small cell lung cancer ( NSCLC) . Methods Plasma DNAs solated fromblood specimens of 170 NSCLC patients, who were admitted in the First Affiliated Hospital of uangzhou Medical College from December 2005 to December 2007, were subjected to the test of EGFR utant-enriched PCR. The correlation of mutant detection with clinical characteristics was analyzed as well.Results Out of the total 170 patients, EGFR mutations were identified in 77 cases ( 77 /170, 45. 3% ) .EGFR mutations were more frequent in the patients with adenocarcinoma ( P lt; 0. 001) and in the nonsmokers P =0. 001) . In the 33 patients treated with gefitinib, those with mutations ( + ) showed a higher esponse rate and prolonged progression-free survival after the treatment compared with those with mutations( - ) ( P =0. 001 and 0. 001, respectively) . Conclusions EGFR active mutations can be specifically and ensitively detected by EGFR mutant enriched PCR assay. Plasma EGFR mutants detection is valuable in uiding clinical decision.

    Release date:2016-09-13 04:07 Export PDF Favorites Scan
8 pages Previous 1 2 3 ... 8 Next

Format

Content